A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection

We generated an optimized COVID-19 vaccine candidate based on the modified vaccinia virus Ankara (MVA) vector expressing a full-length prefusion-stabilized SARS-CoV-2 spike (S) protein, termed MVA-CoV2-S(3P). The S(3P) protein was expressed at higher levels (2-fold) than the non-stabilized S in cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Pérez, Patricia, Lázaro-Frías, Adrián, Zamora, Carmen, Sánchez-Cordón, Pedro J., Astorgano, David, Luczkowiak, Joanna, Delgado, Rafael, Casasnovas, José M., Esteban, Mariano, García-Arriaza, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8829548/
https://www.ncbi.nlm.nih.gov/pubmed/35154086
http://dx.doi.org/10.3389/fimmu.2021.824728

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8829548/
https://www.ncbi.nlm.nih.gov/pubmed/35154086
http://dx.doi.org/10.3389/fimmu.2021.824728

Ejemplares similares